Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression.

ABSTRACT:

Objective

Treatment-resistant depression has recently emerged as a marker of increased risk for morbidity and mortality in patients with coronary heart disease (CHD). Studies in depressed patients without CHD suggest that elevated markers of inflammation predict poor response to treatment. This may help to explain the increased risk of cardiac events associated with depression. We therefore studied the relationship between pretreatment markers of inflammation and treatment response in patients with CHD and major depression.

Methods

This was a planned, secondary analysis of a clinical trial in which 122 patients with CHD and comorbid major depression were randomly assigned to 50 mg of sertraline plus 2 g/day omega-3 fatty acids or to 50 mg of sertraline plus 2 g/day corn oil

SUBMITTER: Bot M 

PROVIDER: S-EPMC3115530 | biostudies-literature | 2011 Jul

REPOSITORIES: biostudies-literature